DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Coverage details, prior authorization criteria, copay ranges, and appeal strategy for 2026. Verified May 1, 2026.
Coverage varies sharply by plan. Commercial PPO plans typically cover GLP-1s with PA. Medicare Advantage plans follow Part D rules — weight-loss indication blocked, T2D + obesity-with-comorbidity covered.
Aetna requires the following before approving Ozempic:
Top denial patterns we see in 2026 based on appeal-claim data:
For T2D patients: ensure A1C >6.5% on lab record. Aetna denies off-label aggressively — clinical notes must justify T2D indication.
Aetna Member Services → Medical Necessity Appeal → fax or upload through Aetna member portal.
Ozempic (semaglutide 0.5-2mg) carries the following FDA-approved indications. Off-label use is the #1 PA denial reason — ensure your prescribing diagnosis matches one of these.
Coverage details verified May 1, 2026 against Aetna formulary documentation. Formulary changes happen quarterly — always verify against your specific plan before prescribing.